Remove Arrhythmia Remove Atrial Fibrillation Remove Risk Factors
article thumbnail

Effects of 1-year exercise in patients with atrial fibrillation: study protocol for the Norwegian Exercise in Atrial Fibrillation (NEXAF) randomised controlled trial

Open Heart

Introduction Atrial fibrillation is the most prevalent sustained arrhythmia worldwide and is expected to increase substantially within the coming years. Eligible patients are randomised 1:1 to either a combined supervised and eHealth-based exercise intervention or usual care for 12 months.

article thumbnail

iRhythm Unveils New Data Demonstrating Benefits of Long-Term Continuous Monitoring for Arrhythmia Detection

DAIC

arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden. arrhythmia yield versus 69.1% in daily-symptom patients, demonstrating that greater symptom frequenc y does not necessarily reflect increased arrhythmia burden.

article thumbnail

News from EHRA 2024: International Experts Agree on Standards for Catheter Ablation of Atrial Fibrillation

DAIC

An international consensus statement on how to treat atrial fibrillation with catheter or surgical ablation has been published in EP Europace, a journal of the European Society of Cardiology (ESC), and was recently presented at EHRA 2024, a scientific congress held April 7-9 in Berlin, Germany.

article thumbnail

Biosense Webster Submits Application to U.S. FDA Seeking Approval of the VARIPULSE Platform for the Treatment of Paroxysmal Atrial Fibrillation

DAIC

a global leader in cardiac arrhythmia treatment and part of Johnson & Johnson MedTec h i , announced the submission of the VARIPULSE Platform for Premarket Approval Application (PMA) to the U.S. 2,3 Approximately 1 in 4 adults over the age of 40 are at risk for developing AFib. Food & Drug Administration ( FDA ). Int J Stroke.

article thumbnail

Late-breaking Clinical Trial Results from FARADISE, adMIRE Study and Advent Trial at Heart Rhythm 2024 Highlight Pulsed Field Ablation Developments for Atrial Fibrillation Treatment

DAIC

During its Annual Conference, HRS 2024, the Heart Rhythm Society (HRS) announced findings from three new studies demonstrating the safety and efficacy of pulsed field ablation (PFA), a nonthermal ablation treatment for patients with atrial fibrillation (AF). See full findings from the FARADISE, admIRE Study, and Advent Trial here.

article thumbnail

Patients diagnosed with new-onset, persistent AFib are more likely to have certain risk factors

Medical Xpress - Cardiology

Patients who present with persistent atrial fibrillation at diagnosis are more likely to have certain risk factors as compared with patients with occasional atrial fibrillation (AFib).

AFIB 74
article thumbnail

2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines

Circulation

Additional relevant studies, published through November 2022, during the guideline writing process, were also considered by the writing committee and added to the evidence tables, where appropriate.StructureAtrial fibrillation is the most sustained common arrhythmia, and its incidence and prevalence are increasing in the United States and globally.